Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Resveratrol and inflammation : challenges in translating pre-clinical findings to improved patient outcomes. / Poulsen, Morten Møller; Fjeldborg, Karen; Ornstrup, Marie Juul; Kjær, Thomas Nordstrøm; Nøhr, Mark Klitgaard; Pedersen, Steen Bønløkke.

I: B B A - Molecular Basis of Disease, Bind 1852, Nr. 6, 2015, s. 1124-1136.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Poulsen, MM, Fjeldborg, K, Ornstrup, MJ, Kjær, TN, Nøhr, MK & Pedersen, SB 2015, 'Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes', B B A - Molecular Basis of Disease, bind 1852, nr. 6, s. 1124-1136. https://doi.org/10.1016/j.bbadis.2014.12.024

APA

Poulsen, M. M., Fjeldborg, K., Ornstrup, M. J., Kjær, T. N., Nøhr, M. K., & Pedersen, S. B. (2015). Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes. B B A - Molecular Basis of Disease, 1852(6), 1124-1136. https://doi.org/10.1016/j.bbadis.2014.12.024

Vancouver

Poulsen MM, Fjeldborg K, Ornstrup MJ, Kjær TN, Nøhr MK, Pedersen SB. Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes. B B A - Molecular Basis of Disease. 2015;1852(6):1124-1136. https://doi.org/10.1016/j.bbadis.2014.12.024

Author

Poulsen, Morten Møller ; Fjeldborg, Karen ; Ornstrup, Marie Juul ; Kjær, Thomas Nordstrøm ; Nøhr, Mark Klitgaard ; Pedersen, Steen Bønløkke. / Resveratrol and inflammation : challenges in translating pre-clinical findings to improved patient outcomes. I: B B A - Molecular Basis of Disease. 2015 ; Bind 1852, Nr. 6. s. 1124-1136.

Bibtex

@article{60026779e68d4f478179f53827410d11,
title = "Resveratrol and inflammation: challenges in translating pre-clinical findings to improved patient outcomes",
abstract = "Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.",
keywords = "Adipose Tissue/drug effects, Animals, Anti-Inflammatory Agents, Non-Steroidal/pharmacology, Clinical Trials as Topic, Humans, Inflammation/drug therapy, Obesity/drug therapy, Stilbenes/pharmacology, Translational Medical Research",
author = "Poulsen, {Morten M{\o}ller} and Karen Fjeldborg and Ornstrup, {Marie Juul} and Kj{\ae}r, {Thomas Nordstr{\o}m} and N{\o}hr, {Mark Klitgaard} and Pedersen, {Steen B{\o}nl{\o}kke}",
note = "Copyright {\circledC} 2015 Elsevier B.V. All rights reserved.",
year = "2015",
doi = "10.1016/j.bbadis.2014.12.024",
language = "English",
volume = "1852",
pages = "1124--1136",
journal = "B B A - Molecular Basis of Disease",
issn = "0925-4439",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Resveratrol and inflammation

T2 - challenges in translating pre-clinical findings to improved patient outcomes

AU - Poulsen, Morten Møller

AU - Fjeldborg, Karen

AU - Ornstrup, Marie Juul

AU - Kjær, Thomas Nordstrøm

AU - Nøhr, Mark Klitgaard

AU - Pedersen, Steen Bønløkke

N1 - Copyright © 2015 Elsevier B.V. All rights reserved.

PY - 2015

Y1 - 2015

N2 - Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

AB - Throughout the Western world obesity prevalence is steadily increasing, and associated metabolic co-morbidities are projected to rise during the years to come. As weight loss and weight maintenance remains a major problem, new strategies to protect against obesity-related morbidity are needed. There is a clear association between obesity, low-grade inflammation and obesity-associated diseases, thus, the development of new anti-inflammatory substances is urgently needed as these may ultimately pave the way for novel treatments of obesity and lifestyle-related diseases. A candidate molecule is the polyphenolic compound resveratrol, and in the present review, we provide an overview of the field, and discuss the future scientific perspectives. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

KW - Adipose Tissue/drug effects

KW - Animals

KW - Anti-Inflammatory Agents, Non-Steroidal/pharmacology

KW - Clinical Trials as Topic

KW - Humans

KW - Inflammation/drug therapy

KW - Obesity/drug therapy

KW - Stilbenes/pharmacology

KW - Translational Medical Research

U2 - 10.1016/j.bbadis.2014.12.024

DO - 10.1016/j.bbadis.2014.12.024

M3 - Review

C2 - 25583116

VL - 1852

SP - 1124

EP - 1136

JO - B B A - Molecular Basis of Disease

JF - B B A - Molecular Basis of Disease

SN - 0925-4439

IS - 6

ER -

ID: 195591641